SCHEMBL2170831

SCHEMBL2170831

CCOC(=O)C(CC)ON=Cc1cc(Br)c(Oc2ccc(OC)c(Cc3ccccc3)c2)c(Br)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
LMNA P02545 5/20 0.40
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 4/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
APP P05067 1/20 0.37
THRA P10827 2/20 0.36
THRB P10828 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PRNP P04156 1/20 0.34
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
MEN1 O00255 2/20 0.34
TNFRSF1A P19438 1/20 0.34
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16496687 1.00 MAPT (0.40) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2169802 0.92 LMNA (0.41) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL16495653 0.92 LMNA (0.41) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2183907 0.86 MAPT (0.41) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL16496323 0.86 MAPT (0.41) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2169685 0.85 LMNA (0.45) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2169683 0.85 LMNA (0.45) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2170382 0.84 MAPT (0.40) MAPTLMNAALDH1A1HPGDPKM
SCHEMBL2171186 0.84 THRB (0.44) MAPTLMNATHRATHRBMAPK1
SCHEMBL16495821 0.84 THRB (0.44) MAPTLMNATHRATHRBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA MAPT 692/4885LMNA 3227/4885ALDH1A1 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.